Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
113 hedge funds and large institutions have $2.52B invested in Sio Gene Therapies Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 44 increasing their positions, 21 reducing their positions, and 18 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 21
100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 18
77% more call options, than puts
Call options by funds: $70.4M | Put options by funds: $39.8M
55% more capital invested
Capital invested by funds: $1.63B → $2.52B (+$897M)
16% more funds holding
Funds holding: 97 → 113 (+16)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$144M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$45.2M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$21.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.9M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Agricole
Montrouge Cedex,
France
|
-$110M |
| 2 |
Millennium Management
New York
|
-$12.3M |
| 3 |
DM
Deerfield Management
New York
|
-$7.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$6.63M |
SIOX Hedge Fund Activity: Q2 2017 in Review
113 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q2 2017, worth a combined $2.52B — up 55% from $1.63B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new SIOX positions and 18 closed out — a net gain of 18 holders — while 44 added to existing stakes and 21 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $144M. The largest seller was Credit Agricole, exiting entirely with an estimated $110M sold.
- 113 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q2 2017, up from 97 in Q1 2017.
- Funds reported $2.52B of Sio Gene Therapies Inc. Common Stock stock for Q2 2017, up 55% quarter-over-quarter.
- 36 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q2 2017 and 18 closed out, a net change of +18 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q2 2017 was Fidelity Investments, an estimated $144M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q2 2017 was Credit Agricole, an estimated $110M sold.
Based on aggregated 13F filings for Q2 2017.